芪胶升白胶囊治疗毒性弥漫性甲状腺肿合并白细胞减少症临床效果观察  

Clinical effect of Qijiaoshengbai capsule on toxic diffuse goiter complicated with leukopenia

作　　者：葛香妍 郝珊瑚 张文文 纪立秋 李根 王有超 张国旭 GE Xiang-yan;HAO Shan-hu;ZHANG Wen-wen;JI Li-qiu;LI Gen;WANG You-chao;ZHANG Guo-xu(Department of Nuclear Medicine,General Hospital of Northern Theater Command,Shenyang 110016,China)

机构地区：[1]北部战区总医院核医学科,辽宁沈阳110016

出　　处：《临床军医杂志》2024年第7期674-677,共4页Clinical Journal of Medical Officers

基　　金：辽宁省自然基金项目(20180550191)。

摘　　要：目的探讨芪胶升白胶囊治疗毒性弥漫性甲状腺肿(GD)合并白细胞(WBC)减少症的临床效果。方法选取北部战区总医院自2018年1月至2021年11月收治的128例GD合并WBC减少症患者为研究对象。根据不同的治疗方式将患者分为A组与B组,每组各64例。A组患者采用常规抗甲状腺药物+WBC升高疗法。B组患者采用常规抗甲状腺药物+芪胶升白胶囊治疗。比较两组患者的治愈率与治疗有效率。分别于治疗前及治疗后1、3、6个月,记录并比较两组患者WBC、游离三碘甲状腺原氨酸(FT3)、游离四碘甲状腺原氨酸(FT4)、促甲状腺激素(TSH)、促甲状腺素受体抗体(TRAb)水平及甲状腺肿大程度。记录两组患者不良反应发生情况。结果A组患者的治愈率为75.00%(48/64),低于B组的89.06%(57/64),两组比较,差异有统计学意义(P<0.05)。A组、B组患者治疗的有效率分别为92.19%(59/64)、93.75%(60/64),两组比较,差异无统计学意义(P>0.05)。治疗后1、3、6个月,B组患者WBC均高于A组,FT3、TRAb均低于A组,差异均有统计学意义(P<0.05);治疗后3、6个月,B组患者FT4、TSH均低于A组,差异均有统计学意义(P<0.05);与治疗前比较,A组、B组治疗后1、3、6个月的WBC、TSH均升高,FT3、FT4、TRAb、甲状腺肿大程度均降低,差异均有统计学意义(P<0.05)。治疗过程及6个月随访过程中,两组患者均未出现明显的不良反应。结论芪胶升白胶囊能有效升高WBC水平,并改善GD相关指标水平,可用于治疗GD合并WBC减少症患者。Objective To investigate the clinical effect of Qijiaoshengbai capsule in the treatment of graves disease(GD)complicated with leukopenia.Methods A total of 128 patients with GD combined with leukopenia admitted to the General Hospital of Northern Theater Command from January 2018 to November 2021 were selected as the study objects.According to different treatment methods,the patients were divided into group A and group B,64 cases in each group.Patients in group A were treated with conventional antithyroid drugs plus white blood cell(WBC)elevation therapy.The patients in group B were treated with conventional antithyroid drugs Qijiaoshengbai capsule.The cure rate and effective rate of the two groups were compared.The levels of WBC,free triiodothyronine(FT3),free thyroxine(FT4),thyroid stimulating hormone(TSH),thyroid stimulating hormone receptor antibodies(TRAb)and goiter in the two groups were recorded and compared before and 1,3 and 6 months after treatment,respectively.The occurrence of adverse reactions was recorded in the two groups.Results The cure rate of group A was 75.00%(48/64),lower than that of group B(89.06%,57/64),the difference was statistically significant(P<0.05).The effective rate of treatment in group A and group B was 92.19%(59/64)and 93.75%(60/64),respectively,with no statistical significance(P>0.05).At 1,3 and 6 months after treatment,WBC in group B was higher than those in group A,and FT3 and TRAb were lower than those in group A,with statistical significance(P<0.05).At 3 and 6 months after treatment,FT4 and TSH in group B were lower than those in group A,with statistical significance(P<0.05).Compared with before treatment,WBC and TSH were increased in group A and group B at 1,3 and 6 months after treatment,while FT3,FT4,TRAb and goiter degree were decreased,with statistical significance(P<0.05).During treatment and 6-month follow-up,no significant adverse reactions occurred in both groups.Conclusion Qijiaoshengbai capsule can effectively increase the level of WBC and improve the level of GD

关 键 词：毒性弥漫性甲状腺肿 白细胞减少症 芪胶升白胶囊 甲状腺素 

分 类 号：R581[医药卫生—内分泌]